Clinical Trials Logo

Clinical Trial Summary

The goal of this observational study is to compare the use of a screw made of human bone (Shark-Screw®, Surgebright-GmbH) with the metal/Bio-Tenodesis screw (Arthrex) in the treatment of the symptomatic flatfoot using the medializing calcaneus osteotomy with flexor digitorum longus transfer (FDL) in adult patients. The advantage of the human bone screw is that after surgery no hardware removal is necessary. The screw is transformed from the body to normal bone. The main questions it aims to answer are: - Can the human bone screw achieve union rates like the metal/Bio-Tenodesis screw? - Is the time to union similar between the different screws? - Is the complication rate similar between the different screws? - Are the activity scores American Orthopaedic Foot and Ankle Society (AOFAS), Foot and Ankle Outcome Score (FAOS) and Foot Function Index (FFI) after surgery similar in the compared patient groups? Participants will have - the surgery - follow-ups at 6 weeks, 6 months, 1 and 2 years. - X-rays are performed at each follow up. - CT-scans are performed after 6 months. - activity scores are collected at the follow up after 6 months, 1 year and 2 years.


Clinical Trial Description

Symptomatic flatfoot deformity in adults often occurs as a result of dysfunction of the Tibialis posterior tendon (TPTD), with a prevalence of 3.3%. Structured non-surgical treatment programs with orthotics and physiotherapy can achieve a high level of long-term subjective and functional satisfaction, with surgery being avoided in 70-89% of cases. Surgical intervention is indicated for progressive or uncontrolled symptoms. Flexible flatfoot deformity, stage II classified by Johnson and Strom, can be treated with a joint-preserving strategy, which usually includes a medializing calcaneal osteotomy, debridement of the tibialis posterior tendon, and transfer of the flexor digitorum longus (FDL) tendon. 87% satisfaction after ten years was observed in both pain relief and foot function and alignment. Metal screws have been used for decades to treat bone fractures. The removal is the major disadvantage of conventional osteosyntheses and requires a second operation, with all the resulting risks of complications for each patient. The use of the bone screw from allogeneic cortical bone would reduce costs substantially, with a significant reduction in the average complication rate to 0.3%. The idea of stabilizing fractures using compact bone instead of metal is not new. Obwegeser published the clinical use of 796 screw implants of allogeneic bone and reported that the only complication was the fracture of 6 screws (<1%) and three screw loosening (<0,5%). Since 2016, the human, allogeneic cortical bone screw(Shark Screw®) has been used by two tissue banks, the Austrian Austrian tissue bank Surgebright-GmbH and the German Institute for Cell and Tissue Replacement (DIZG). The Shark Screw® graft was approved by the competent Austrian authority (AGES) in 2016. The bone graft immediately creates a solid, purely bony connection. This leads to bone remodeling, bone incorporation and optimal reparation in the surgical area. Depending on the loads and requirements, the bone connection adapts for the future. The bone grafts undergo a certified sterilization procedure at the DIZG, which was developed in 1985 at the Berlin Charité. Due to the lack of further systematic investigations to objectively confirm the theoretically given and subjectively experienced product advantages, this observational study is now being conducted. The aim of the present study is to evaluate the application of the human allogeneic cortical bone screw (Shark Screw®) and the metal/Bio-Tenodesis screw in the surgical treatment (medializing calcaneus osteotomy with FDL transfer) of symptomatic flatfoot and to systematically document corresponding clinical and radiological parameters before and after surgery. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05643079
Study type Observational
Source Orthopedic Hospital Vienna Speising
Contact Florian Wenzel-Schwarz, MD
Phone +43180182
Email florian.wenzel-schwarz@oss.at
Status Recruiting
Phase
Start date February 10, 2022
Completion date February 2028

See also
  Status Clinical Trial Phase
Not yet recruiting NCT06112145 - Are Rehabilitation Results in Flexor Tendon Zone II Injuries as Bad as Feared? N/A
Not yet recruiting NCT05095415 - Occupational Therapy Pre-operative Education in the Orthopedic Hand Setting N/A
Completed NCT04237415 - Electromyographic (EMG) Biofeedback Training in Zone I-III Flexor Tendon Injuries N/A
Completed NCT05188040 - Effectiveness of Virtual Reality in Hand Therapy N/A
Completed NCT06198582 - The Effect of Virtual Reality Based Task Specific Exercises in Patients With Hand Flexor Tendon Injury N/A
Recruiting NCT06149962 - Comparison Between Functional Outcomes of Flexor Tendon Repair Under WALANT and Brachial Plexus Block N/A
Recruiting NCT05148585 - Efficacy Of Activity-Based Intervention On Activity, Participation And Kinesiophobia In Patients With Tendon Injury N/A
Completed NCT05809102 - Repair Of Flexor Tendon In Zone II Using Minimal Incisions N/A
Not yet recruiting NCT04579809 - Results of Flexor Tendon Repair of the Hand in Children Below Six Years of Age N/A
Recruiting NCT05093946 - Psychometric Measurement Properties of the Michigan Hand Questionnaire in Patients After Flexor Tendon Repair
Recruiting NCT05078476 - Rehabilitation of Finger Flexor Tendon Injuries N/A